Neuronetics reports Q4 EPS (33c), consensus (24c)

Reports Q4 revenue $22.49M, consensus $18.98M. “2024 was a defining year for Neuronetics (STIM) as we’ve strategically transformed our business model and market position,” said Keith Sullivan, President and Chief Executive Officer of Neuronetics. “By expanding our Better Me Provider network and acquiring Greenbrook, we’ve created an unparalleled TMS treatment platform while rapidly improving our financial position.”